Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quantum BioPharmaSTU:0K91 -6.84%38 EV-to-FCF is -2.45 as of Jul. 21, 2026. GuruFocus rates STU:0K91 with a GF Score™ of 38/100. The stock has 5 warning signs investors should review. Among 338 Biotechnology companies, Quantum BioPharma ranks worse than 295857.69% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Quantum BioPharma's Enterprise Value is €11.90 Mil.
Quantum BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.86 Mil. Therefore, Quantum BioPharma's EV-to-FCF for today is -2.45.
The historical rank and industry rank for Quantum BioPharma's EV-to-FCF or its related term are showing as below:
STU:0K91'
s EV-to-FCF Range Over the Past 10 Years
Min: -301.76 Med: -0.36 Max: 0.26
Current: -2.48
During the past 11 years, the highest EV-to-FCF of Quantum BioPharma was 0.26. The lowest was -301.76. And the median was -0.36.
STU:0K91's EV-to-FCF is ranked worse than 100% of 338
companies
in the Biotechnology industry
Industry Median: 15.02
vs STU:0K91: -2.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Quantum BioPharma's PE Ratio (TTM) for today is calculated as:
Quantum BioPharma's share price for today is €2.642.
Quantum BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.118.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Quantum BioPharma EV-to-FCF Related Terms
Quantum BioPharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Quantum BioPharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0K91 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Quantum BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quantum BioPharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quantum BioPharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Quantum BioPharma's EV-to-FCF falls into.
Quantum BioPharma's current Enterprise Value is €11.90 Mil.
Quantum BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quantum BioPharma (STU:0K91) has a EV-to-FCF of -2.45 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Quantum BioPharma and its competitors. According to the industry distribution chart, Quantum BioPharma ranks #999999 out of 338 companies in the Biotechnology industry.
Is Quantum BioPharma's EV-to-FCF too high?
Quantum BioPharma's current EV-to-FCF is -2.45. Based on the distribution chart, Quantum BioPharma ranks #999999 out of 338 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Quantum BioPharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Quantum BioPharma's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quantum BioPharma ranks #999999 out of 338 companies for EV-to-FCF. This places Quantum BioPharma in the lower half of its industry. The industry median EV-to-FCF is 15.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.02, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Quantum BioPharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quantum BioPharma's current EV-to-FCF is -2.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quantum BioPharma stock overvalued right now?
Quantum BioPharma (STU:0K91) has a current EV-to-FCF of -2.45. The current EV-to-FCF is -2.45. Quantum BioPharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Quantum BioPharma (STU:0K91), the current EV-to-FCF is -2.45 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
38GF Score
Get the complete analysis for STU:0K91
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0K91 has been successfully added to your 
